Uncategorized
Common Pitfalls That Delay Regulatory Submissions, and How to Prevent Them
Common Pitfalls That Delay Regulatory Submissions, and How to Prevent Them
Common early-phase pitfalls, from misaligned nonclinical strategy to gaps in CMC, bioanalysis, and species selection, can delay IND and CTA submissions. By aligning development plans with regulatory expectations from the outset and integrating cross-functional insight, sponsors can reduce rework, strengthen submissions, and maintain momentum toward first-in-human studies. Read More